Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663679 | 0.81 | CYP1A2 (0.39) | KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6660581 | 0.81 | MEN1 (0.38) | NPC1MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6659090 | 0.80 | TLR4 (0.38) | MAPTRAB9ASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL6661549 | 0.77 | CA1 (0.35) | KMT2A | |
| SCHEMBL21050037 | 0.70 | ALDH1A1 (0.49) | KDM4ENPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL14999835 | 0.68 | KMT2A (0.40) | KDM4ESMN1; SMN2KMT2A | |
| SCHEMBL7044903 | 0.68 | — | — | |
| SCHEMBL7044900 | 0.68 | — | — | |
| SCHEMBL6664642 | 0.67 | CYP1A2 (0.42) | KDM4ENPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31520822 | 0.63 | LMNA (0.40) | KDM4ENPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244615-B1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER CROPSCIENCE AG (DE) | 2004-08-11 | — | — | EP | disclosed |
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-23 | — | — | US | disclosed |
| EP-1244615-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001047873-A1 | METHOD FOR PRODUCING N-SUBSTITUTED 2,4-DIAMINO-5-FLUORO BENZONITRILES AND NOVEL INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030017948-A1 | Method for producing n-substituted 2,4-diamino-5-fluoro benzonitriles and novel intermediates | DDT, PFAS, DAO | CNKSR1 3629/4885KDM4E 915/4885NPC1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.